Dublin, Dec. 23, 2016 -- Research and Markets has announced the addition of the "Glioblastoma Drugs Price Analysis and Strategies - 2016" report to their offering.
Glioblastoma Drugs Price Analysis and Strategies 2016, provides drug pricing data and benchmarks in the global Glioblastoma market.
The research answers the following questions:
- What are the key drugs marketed for Glioblastoma and their clinical attributes? How are they positioned in the Global Glioblastoma market?
- What are the unit prices and annual treatment cost for Glioblastoma therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
- What are the unmet needs in the global Glioblastoma drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Glioblastoma?
Research Scope:
- Treatment Options - Identify key drugs marketed and prescribed for Glioblastoma including trade name, molecule name, and company
- Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Glioblastoma
- Market Positioning - Identify how drugs are clinically and commercially positioned in the global Glioblastoma market
- Glioblastoma Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed
- Find out how the price advanced from 2012 and forecast to 2021
- Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape
- Glioblastoma New Drug Pricing - Identify the effective pricing strategy for a new drug launch
Key Topics Covered:
1. Treatment Options
2. Drugs Clinical Attributes
3. Drugs Market Positioning
4. Drugs Price Analysis
5. Drugs Price Benchmarks
6. Drug Pricing & Reimbursement Landscape
7. Drugs Price Forecast
8. Market Unmet Needs
9. New Drug Pricing
For more information about this report visit http://www.researchandmarkets.com/research/9kxxzk/glioblastoma
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Brain Cancer Drugs


Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Bank of America's $72.5M Epstein Settlement: What You Need to Know
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 



